BOSTON, Jan. 9, 2024 /PRNewswire/ -- Recently, Medicilon appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit.

波士顿，2024年1月9日/PRNewswire/--最近，Medicilon任命张海舟博士为临床前研发部门总裁。

Continue Reading

继续阅读

Dr. Zhang

张博士

Medicilon, the pioneer integrated pharmaceutical R&D preclinical services that offers chemistry, DMPK/PD, CMC, toxicology (GLP and non-GLP, we have 2000+ monkeys are available in house), biology services to pharmaceutical and biotech companies around the world. Since 2009, Medicilon's preclinical experimental base has established research processes and quality systems that conform to international standards.

Medicilon是领先的综合药物研发临床前服务公司，为世界各地的制药和生物技术公司提供化学，DMPK/PD，CMC，毒理学（GLP和非GLP，我们有2000多只猴子在家），生物学服务。自2009年以来，Medicilon的临床前实验基地建立了符合国际标准的研究流程和质量体系。

It has successively passed AAALAC, GLP, NMPA, FDA, TGA, EMEA, etc., providing global pharmaceutical companies and research institutions with comprehensive preclinical pharmaceutical research and professional development services. The Medicilon Preclinical R&D Unit is composed of experienced experts and international advanced technology platforms to support clients' projects and promote the new drug industry.

先后通过AAALAC、GLP、NMPA、FDA、TGA、EMEA等认证，为全球制药公司和研究机构提供全面的临床前药物研究和专业开发服务。Medicilon临床前研发部门由经验丰富的专家和国际先进技术平台组成，以支持客户的项目并促进新药行业。

The joining of Dr. Zhang Haizhou will further strengthen Medicilon's strength and competitiveness in preclinical research..

张海洲博士的加入将进一步增强Medicilon在临床前研究中的实力和竞争力。。

Dr. Zhang Haizhou holds a PhD in Toxicology from Indiana University, USA. He is a pharmaceutical industry veteran with over 20 years of experience in the R&D of small and large molecule drugs. Prior to joining Medicilon, Dr. Zhang had working experience in health authorities, multinational pharmaceutical companies, and CROs.

张海洲博士拥有美国印第安纳大学毒理学博士学位。他是制药行业的资深人士，在小分子和大分子药物的研发方面拥有20多年的经验。在加入Medicilon之前，张博士曾在卫生部门，跨国制药公司和CRO工作过。

As a seasoned executive and experienced R&D leader, he also has hands-on experience of preparing R&D and BD strategy, regulatory documents such as IND/CTA, NDA/MAA etc. and experience of building R&D teams, operation/compliance systems and initiating and managing collaborations with key business partners..

作为一名经验丰富的高管和经验丰富的研发领导者，他还拥有制定研发和BD战略、IND/CTA、NDA/MAA等监管文件的实践经验，以及建立研发团队、运营/合规系统以及启动和管理与关键业务伙伴合作的经验。。

As an expert in pharmaceutical R&D, Dr. Zhang Haizhou also served in various international organizations. He was a review expert of National Key Innovative Drug R&D Projects of the Ministry of Science and Technology, and also served as an invited guideline reviewer of NMPA and has participated in drafting and reviewing >10 guidelines including the guideline on biosimilars issued in Feb.

作为药物研发专家，张海舟博士还曾在多个国际组织任职。他是科技部国家重点创新药物研发项目的评审专家，也是NMPA的特邀指南评审员，并参与了包括2月发布的生物仿制药指南在内的10多个指南的起草和评审。

2015. He is the Vice Chair of Chinese Society of Quality Assurance in Toxicological Research, a committee member of Drug Safety Evaluation and Research Committee, Chinese Pharmaceutical Association and Drug Toxicology and Safety Evaluation Committee, Chinese Society of Pharmacology. In addition, Dr.

2015年。他是中国毒理学研究质量保证学会副理事长，中国药学协会药物安全评价与研究委员会委员，中国药理学学会药物毒理学与安全评价委员会委员。此外，博士。

Zhang was the founding group leader of the RDPAC Preclinical Focus Group, a former member of board of directors of Chinese Society of Toxicology and Genetic Toxicology Association (USA), etc.Dr. Chen Chunlin, founder of Medicilon, said: 'We are pleased to have Dr. Zhang Haizhou join us. His rich experience will inject new vitality into Medicilon.

张是RDPAC临床前焦点小组的创始小组组长，曾任中国毒理学学会和遗传毒理学协会（美国）董事会成员等。Medicilon创始人陈春林博士表示：“我们很高兴张海舟博士加入我们。他的丰富经验将为Medicilon注入新的活力。

'Website: https://www.medicilon.com/SOURCE Medicilon Inc..

'网站：https://www.medicilon.com/SOURCE美第西隆股份有限公司。。